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Adenovirus (ADV) is an important cause of viral mortality in hematopoietic stem cell transplantation (HSCT).
Recipients of T celledepleted (TCD) HSCT are at increased risk for viral infections. We compared the rates and
outcomes of ADV viremia and disease between TCD and conventional (CONV) HSCT at our institution. This
was an observational study of 624 adult and pediatric recipients of myeloablative HSCT at Memorial Sloan-
Kettering Cancer Center between January 1, 2006, and March 11, 2011. Viral cultures and ADV PCR were
ordered as clinically indicated. ADV viremia by quantitative PCR assay was deﬁned as 1 or more positive
values 1,000 copies/mL or 2 or more consecutive positive values. Competing-risk regression analyses were
used to identify predictors for ADV viremia. ADV viremia at 1 year after HSCT occurred in 8% of TCD HSCT
recipients and in 4.0% of CONV HSCT recipients (P ¼ .041). Among the TCD recipients, ADV viremia was seen in
15% of children, compared with 5% of adults (P ¼ .008). Young age (hazard ratio [HR], 3.0; P < .001) and acute
graft-versus-host disease (GVHD) (HR, 3.2; P ¼ .001) were identiﬁed as risk factors for ADV viremia. ADV
viremia was predictive of mortality (HR, 6.0; P < .001). ADV disease developed in 3.5% of TCD HSCT recipients
and in 0.4% of CONV HSCT recipients (P ¼ .022), with an attributable mortality of 27%. Among TCD HSCY
recipients, grade II to IV GVHD was a risk factor for ADV disease (HR, 13; P < .001), but age was not. More than
90% of the cases of ADV disease involved a viral load of 10,000 copies/mL. Rates of ADV disease were 10-fold
greater in TCD HSCT recipients compared with CONV HSCT recipients, predominantly in patients who
developed acute GVHD. The beneﬁt of preemptive therapy for an ADV viral load 10,000 copies/mL for
preventing ADV disease in TCD HSCT recipients should be evaluated in prospective clinical trials.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION
Adenovirus (ADV) is an important viral pathogen in hema-
topoietic stem cell transplantation (HSCT). ADV-associated
hepatitis, pneumonitis, and encephalitis are frequently fatal,
andcolitis andhemorrhagic cystitiscausesubstantialmorbidity
and may contribute to mortality [1-3]. The relative contribu-
tion of ADV as a viral cause of mortality in HSCT has increased
over thepast decade, possibly related to a strikingdecline in the
rate of cytomgalovirus (CMV)-related mortality [4,5].
Quantitative PCR assays for detection andquantiﬁcation of
ADV in the blood have been commercially available since
2004. Some groups have advocated serial monitoring for ADV
byPCRduring theﬁrst 6months afterHSCTor for the duration
of severe immunosuppression and/or lymphopenia [6]. This
practice has not been widely adopted in clinical practice,
however, owing mainly to the lack of safe and effectivedgments on page 392.
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12.10.014treatment for ADV. In addition, the natural history of ADV
viremia in HSCT is not well deﬁned. Reported rates of post-
HSCT ADV viremia vary widely, ranging from 4.9% to 25.8%,
depending on the surveillance strategy and patient pop-
ulation [2,7-9]. Ohrmalm et al. [7] found little utility in serial
monitoring of plasma ADV PCR in a cohort of 97 HSCT recip-
ients, 64% of whom received a Tcelledepleted (TCD) allograft
[7]. High-level or rising ADV viremia has been reported to
predict disseminated ADV disease and death [10-13].
Increasing ADV viral load in the stool has also been identiﬁed
as a useful predictor of ADV disease [12]. T cell depletion,
youngerage, and graft-versus-host disease (GVHD)havebeen
associated with invasive ADV disease [1,10-12].
Although preemptive treatment for ADV viremia could
potentially prevent ADV disease, currently there are no data
from randomized clinical trials to support its application.
Furthermore, at present, there is no approved therapy for
ADV. Cidofovir has been used in patients with established
ADV disease, but its efﬁcacy is not well documented.
CMX001, a novel orally administered broad-spectrum anti-
viral active against ADV, has shown promising results in case
reports [10,14,15]. A clinical trial of preemptive treatment of
ADV viremia with CMX001 for prevention of ADV disease in
HSCT recipients is ongoing.Transplantation. Published by Elsevier Inc. All rights reserved.
Table 1
Clinical Characteristics of HSCT Recipients (n ¼ 624)
Characteristic TCD HSCT
(n ¼ 401)
CONV HSCT
(n ¼ 223)*
P Value
Age, y, median (range) 47.5 (0.1-73) 31.8 (0.4-69.9) <.001
Sex, n (%)
Male 230 (57.4) 122 (54.7) .52
Female 171 (42.6) 101 (45.3)
Underlying disease, n (%)
Acute leukemia 231 (57.6) 135 (60.5)
Lymphoma 22 (5.5) 37 (16.6)
Myelodysplastic syndrome 64 (16) 18 (8.1)
Multiple myeloma 28 (7.0) 0
Nonmalignant 44 (11.0) 20 (9.0)
Chronic myelogenous
leukemia
9 (2.2) 7 (3.1)
Othery 3 (0.7) 6 (2.7)
Stem cell source, n (%)
Peripheral blood 372 (92.8) 83 (37.2) <.001
Bone marrow 29 (7.2) 48 (21.5)
Cord blood 0 92 (41.3)
Donor type, n (%)
Matched related donor 132 (32.9) 69 (30.9) <.001
Matched unrelated donor 136 (33.9) 51 (22.9)
Mismatched related donor 16 (4) 0
Mismatched unrelated donor 117 (29.2) 11 (4.9)
Cord blood 92 (41.3)
Acute GVHD, n (%)
Grade 0-I 341 (85.1) 124 (55.6) <.001
Grade II 25 (6.2) 46 (20.6)
Grade III-IV 21 (5.2) 40 (18)
Nonevaluable 14 (3.5) 13 (5.8)
* CONV includes recipients of peripheral blood, bone marrow, and cord
blood allografts.
y Other includes sarcoma and chronic lymphocytic leukemia.
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ADV disease was 1.3%, with the majority of cases occurring in
TCD HSCT recipients [2]. Since 2006, we have used ADV PCR
to evaluate patients with clinical symptoms suggestive of
ADV infection or disease.We conducted a retrospective study
to identify risk factors for ADV viremia and disease and to
compare rates and outcomes of ADV disease in recipients of
TCD HSCT and conventional (CONV) HSCT.
METHODS
Patients
The study was reviewed and approved by the Memorial Sloan-Kettering
Cancer Center (MSKCC) Institutional Review Board. The cohort comprised
624 adult and pediatric patients who underwent a ﬁrst myeloablative
allogeneic HSCT at MSKCC between January 1, 2006, and March 11, 2011.
Patients were followed up to September 2011 or death, whichever occurred
ﬁrst; minimum follow-up was 6months. The procedures for T cell depletion,
supportive care, and management of GVHD were described previously
[16-18]. Starting in July 2006, a Miltenyi Biotech MACS system was used for
T cell depletion, in a total of 106 allografts. Recipients of TCD grafts did not
receive additional immunosuppression for GVHD prophylaxis.
Clinical and laboratory data were extracted from a computerized
prospective database. Antiviral treatment and outcomes were extracted
from pharmacy and medical records.
Deﬁnitions
There was no routine surveillance for ADV during the study period;
rather, blood, ADV PCR, and viral cultures were ordered at the discretion of
treating physicians. In this study, patients not tested by ADV PCR and those
with negative ADV PCR results were considered negative for ADV viremia.
ADV infection was deﬁned as a positive culture for ADV from a nonsterile
site (eg, stool, urine, nasopharynx). ADV viremiawas diagnosed by ADV PCR.
A patient with at least 1 PCR value of 1,000 copies/mL or at least 2
consecutive positive PCRs of any value was considered to have ADV viremia.
The time to ADV viremia was deﬁned as the days from the date of stem cell
infusion (d0) to the ﬁrst positive ADV PCR report meeting the deﬁned
criteria. High-level ADV viremia was deﬁned as at least 1 PCR value of
10,000 copies/mL, and very-high-level ADV viremia was deﬁned as at least
1 PCR value of 200,000 copies/mL at any time point. Viremia was
considered early if it occurred 180 days after transplantation. ADV end-
organ disease has been deﬁned previously [1,12]. Deﬁnite disease was
deﬁned as the presence of typical ADV nuclear inclusions or positive
immunohistochemistry for ADV in tissue and/or positive culture from tissue
(excluding the gastrointestinal tract). Probable ADV disease was deﬁned as
at least 2 positive ADV PCR reports along with clinical signs and symptoms
compatible with ADV disease with no other identiﬁed cause. Disseminated
ADV disease was deﬁned as the presence of ADV by culture or histopa-
thology, along with clinical evidence of disease in at least 2 noncontiguous
sites, excluding blood. Death was attributed to ADV if ADV caused or
signiﬁcantly contributed to death.
Laboratory Methods
Routineviral cultures forADVwereperformed in theClinicalMicrobiology
Laboratory at MSKCC. Quantitative real-time ADV PCR in whole blood was
performed by Focus (Cypress, CA) until June 2009 and by Viracor-IBT (Lee’s
Summit, MO) thereafter. The linear range of quantitation was 250-1  108
copies/mL at the former laboratory and 100-1 1010 copies/mL at the latter.
Statistics
Binary variables were compared using the c2 or Fisher exact test.
Continuous variables were compared using the Mann-Whitney U test.
Cumulative incidence rates for ADV in the stool and ADV viremia were
estimated by cumulative incidence analysis, with death treated as
a competing risk. Patients were censored at the date of the second HSCT or
the last follow-up, whichever occurred ﬁrst. Cumulative incidence rates in
TCD HSCT recipients and CONVHSCT recipients throughout the study period
were compared using Gray’s test. The Wald test was used to compare rates
at 1 year and 2 years after HSCT. Permutation testing was usedwhen a group
had fewer than 5 events [19].
Competing-risk regression was used to identify risk factors for ADV
viremia and disease. Hazard ratios (HRs) and 95% conﬁdence intervals (CIs)
were estimated. Time-dependent Cox regression was used to assess for an
association between ADV viremia and overall survival (OS). Statistical
analyses were performedwith SAS version 9.2 (SAS Institute, Cary, NC) and R
version 2.13 (R Foundation for Statistical Computing, Vienna, Austria). A P
value .05 was considered statistically signiﬁcant.RESULTS
Patients
Among 624 patients who underwent myeloablative HSCT,
401 received a TCD allograft, 131 received an unmodiﬁed
allograft, and 92 received an umbilical cord blood allograft. In
this study, the category CONV includes unmodiﬁed bone
marrow, peripheral blood, and umbilical cord blood stem cell
allografts. Table 1 presents the clinical characteristics of the
624 study patients. Compared with CONV HSCT recipients,
TCD HSCT recipients were older, received more peripheral
blood mononuclear cell grafts, and had less GVHD.
ADV in the Stool
During the study period, 89.2% CONV HSCT recipients and
72.8% TCD HSCT recipients had at least 1 stool viral culture
(P <.001) obtained for evaluation of diarrhea and/or clinical
symptomsof enteritis or colitis. At 1 year posttransplantation,
10.8% CONV HSCT recipients and 12.7% TCD HSCT recipients
had a positive stool culture for ADV (P ¼ .479). Eighty-two
patients had at least 1 positive stool culture for ADV. Colo-
noscopywas performed in 25 patients (30%). Six patients had
ADV colitis identiﬁed by histopathology.
ADV Viremia
During the study period, 362 patients (58%) underwent
blood testing by ADV PCR. More CONV HSCT recipients than
TCD HSCT recipients underwent ADV PCR (67.7% versus
52.6%; P< .001). Forty-three patients (6.9%) had ADV viremia.
At 1 year, 4% CONV, and 7.9% TCD HSCT recipients had ADV
viremia (P ¼ .04). At 2 years, the difference was not statisti-
cally signiﬁcant (8.3% for TCD versus 5.3% for CONV; P ¼ .16).
Among TCD HSCT recipients, ADV viremiawasmore frequent
in children than in adults (P ¼ .008).
Figure 1 shows the distribution of ADV cases by month
after HSCT. Forty-three patients developed ADV viremia
Figure 1. Distribution of ADV viremia cases by month post-HSCT.
Table 2
Risk Factors for ADV Viremia
Variable HR (95% CI) P Value
Age at HSCT
Adult 1.0 <.001
Pediatric 3.0 (1.6-5.6)
Stem cell source
Peripheral blood 1.0
Bone marrow 1.0 (0.4-2.4) .96
Cord blood 1.4 (0.6-3.2) .42
Graft type
CONV 1.0
TCD 1.8 (0.8-3.3) .15
Donor type
Matched related 1.0
Matched unrelated 0.8 (0.4-1.9) .67
Mismatched 1.1 (0.6-2.2) .78
Acute GVHD grade
0-I 1.0
II-IV 3.2 (1.6-6.3) .001
0-II 1.0
III-IV 5.4 (2.7-11.0) <.001
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a median of 82 days posttransplantation (range, 10-722
days). Thirty-two cases (74%) occurred before 6 months post-
HSCT. One TCD recipient with early ADV viremia (4%) had
grade III to IV GVHD. In contrast, 50% of patients with late
ADV viremia had grade III to IV GVHD.
ADV Viremia and Survival
A time-dependent Cox regression model was used to
estimate the impact of ADV viremia on OS. Patients with ADV
viremia had lower OS compared with those without ADV
viremia (HR, 6.0; 95% CI, 4.1-8.6; P <.001).
Risk Factors for ADV Viremia
On competing regression analyses of 43 patients with
ADV viremia and 581 patients without documented ADV
viremia, young age and acute grade II to IV GVHD were
identiﬁed as risk factors for ADV viremia, whereas T cell
depletion, stem cell source, and donor type were not statis-
tically signiﬁcant risk factors (Table 2). On multivariate
analysis, young age (HR, 2.8; 95% CI,1.5-5; P¼ .001) and acute
grade II to IV GVHD (HR, 3.1; 95% CI, 1.6-6.1; P ¼ .001)
remained independent risk factors for ADV viremia.
ADV Disease
Fifteen patients (2.4%; 14 TCD HSCT recipients and
1 CONV HSCT recipient) developed end-organ ADV disease.
The incidence of ADV disease was higher in TCD HSCT
recipients compared with CONV HSCT recipients (3.5%
versus 0.4%; P ¼ .022). Ten patients had deﬁnite ADV
disease, and 5 had probable ADV disease. ADV colitis
occurred in 6 patients, pneumonitis in 6, hepatitis in 4, and
pyelonephritis/cystitis in 4. Eight patients had ADV
involvement of at least 2 organs.
We performed competing regression analyses to identify
risk factors for ADV disease in the TCD HSCT recipients,
including age, donor type, and GVHD as variables. In our
model, only grade II to IV GVHD was statistically signiﬁcant
(HR, 13.3; 95% CI, 4.5-39.2; P < .001); young age was not
signiﬁcant (HR, 1.5; 95% CI, 0.5-4.4; P ¼ .496).
Eighty-six CONV HSCT recipients and 45 TCD HSCT
recipients had grade II to IV GVHD. ADV disease developed in
1 of the 86 CONV recipients (1.2%) and in 7 of the 45 TCDrecipients (15.5%). Among patients with grade II to IV GVHD,
ADV disease was 15-fold more common in TCD HSCT
recipients compared with CONV HSCT recipients.
We compared characteristics of patients with ADV
disease and those with ADV viremia without disease
(Table 3). Themajority of the patients with ADV disease (93%)
were TCD HSCT recipients, and 40% had grade III-IV GVHD.
The average maximum ADV viral load in ADV disease cases
was 3 log10 higher than that of cases without ADV disease,
although 3 patients with autopsy-proven ADV disease had
a negative ADV PCR report before death.
Ten patients (67%) with ADV disease had a concomitant
opportunistic infection, including CMV, polyoma BK virus,
human herpesvirus 6, Epstein-Barr virus, toxoplasma, and
invasive fungal infection. Fourteen patients (93%) with ADV
disease received antiviral treatment. Treatment was with-
held in 1 patient because it was deemed futile. At 6 months
after diagnosis of ADV viremia, 2 patients (13%) with ADV
disease were alive, compared with 13 patients (46%) with
ADV viremia alone.
Overall, 14 patients (93%) with ADV disease died during
the study period. Death was attributed to ADV in 4 patients
Table 3
Comparison of Patients with ADV Viremia with and without ADV Disease
Characteristics ADV Viremia
Only (n ¼ 28)
ADV Disease
(n ¼ 15)
Age group at HSCT, n (%)
Pediatric 17 (61) 6 (40)
Adult 11 (39) 9 (60)
Stem cell source, n (%)
Peripheral blood 16 (57) 14 (93)
Bone marrow 6 (21.5) 1 (7)
Cord blood 6 (21.5) 0 (0)
Graft type, n (%)
TCD 18 (64) 14 (93)
CONV 10 (36) 1 (7)
Acute GVHD grade, n (%)
0-II 22 (79) 9 (60)
III-IV 6 (21) 6 (40)
Days to ADV viremia, median
(range)
80 (10-722) 125 (20-350)
Days to ADV disease, median
(range)
125 (20-361)
Maximum VL, median copies/mL
(range)
6.9  104
(600-1  107)
2  107
(100->1  1010)
Maximum VL >2  105 copies/mL,
n (%)
9 (32) 11 (73)
ALC, median (range) 319 (0-1471) 336 (17-1208)
Antiviral treatment, n (%) 13 (46) 14 (93)
Resolution of viremia, n (%) 16 (57) 4 (27)
OS at 3 months, n (%) 16 (57) 8 (53)
OS at 6 months, n (%) 13 (46) 2 (13)
VL indicates viral load. OS refers to OS from diagnosis of ADV viremia.
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including disease progression, other infections, and veno-
occlusive disease, in 4 patients (26%).
High ADV Viremia Associated with ADV Disease
Patients with ADV viremia were divided into 3 groups
based on maximum ADV viral load: group 1, <10,000 copies/
mL; group 2, 10,000 copies/mL; and group 3, 200,000
copies/mL. Table 4 summarizes clinical outcomes of the
3 groups. In group 1, viremia resolved spontaneously in 7 of
8 patients (88%) patients; 1 patient with hemorrhagic cystitis
and late-onset grade IV acute GVHD was treated successfully
with CMX001. The 3-month all-cause mortality was 13%, and
no deaths were related to ADV. In comparison, more patients
in group 2 and especially in group 3 received antiviral
treatment, developed ADV end-organ disease, and died from
ADV (Table 4).
Thirteen of 28 patients with ADV viremia (46%) received
antiviral treatment, and ADV viremia resolved in 6 patients.
In contrast, 14 of 15 patients with ADV disease (93%) received
antiviral treatment, and ADV viremia resolved in 4 patients.
Figure 2 compares ﬁrst, maximum, and last available ADVTable 4
Comparison of ADV Viremia Cases by Maximum ADV Viral Load (n ¼ 43)
Variable Group 1 (n ¼ 8) G
Maximum VL, median (range) 3.6  103 (1  102-8866) 1
Days to ADV, median (range) 76.5 (15-480) 7
Pediatric patients, n (%) 6 (75) 1
TCD HSCT, n (%) 7 (88)
GVHD grade III-IV, n (%) 1 (13)*
ADV disease, n (%) 1 (13)
Antiviral treatment, n (%) 1 (13)
Resolution of viremia, n (%) 7 (88)
3-month OS, n (%) 7 (87)
VL indicates viral load.
Group 1: low-level ADV viremia <10,000 copies/mL; group 2: high-level ADV vir
copies/mL). OS refers to OS from the diagnosis of ADV viremia.
* Patient experienced late onset of severe acute GVHD of the skin.viral loads in patients with ADV viremiawithout ADV disease
and patients with ADV disease. The maximum viral load and
last available viral load were signiﬁcantly higher in the
patients with ADV disease (P < .05).DISCUSSION
ADV is an important infectious cause of mortality in HSCT
recipients [1-3,10,20]. Reconstitution of virus-speciﬁc cyto-
toxic T lymphocytes (CTLs) is essential for protection against
viral pathogens after HSCT [21,22]. Recipients of TCD grafts
experience lower rates of GVHD compared with those
receiving conventional allografts, but because there is no
transfer of virus-speciﬁc CTLs from the donor, they are at
increased risk for viral infection. T cell depletion has been
reported as a risk factor for ADV infections, but previous
studies were limited by small sample sizes and variable
degrees of T cell depletion [7,11,22,23].
A limited number of studies have investigated the epide-
miology and natural history of ADV infections in HSCT
recipients through prospective routine monitoring for ADV
[23,24]. Given the relative rarity of ADV disease and lack of
effective and safe therapy, the majority of HSCT centers
currently donot routinelymonitor for ADV in clinical practice.
The main objective of the present study was to describe
the rates and risk factors for ADV disease in the era of ADV
PCR in a cohort of 624 adult and pediatric patients (401 TCD
allografts, 131 conventional allografts, and 92 cord blood
allografts). During the study period, patients with clinical
symptoms compatible with ADV infection were followed
with viral cultures or ADV PCR, as clinically indicated.
Considering the lack of universal routinemonitoring for ADV,
we cannot accurately estimate the true incidence of ADV
viremia in our cohort. Because ADV PCR testing was triggered
by symptoms, patients with ADV viremia would be expected
to be sicker. This ascertainment bias might account for, at
least in part, the relatively high rates of ADV disease and viral
loads in our patients with ADV viremia.
A greater proportion of CONV HSCT recipients than TCD
HSCT recipients were tested for ADV by stool culture or blood
PCR. Higher rates of diarrhea, possibly related to GVHD,might
have triggered more frequent testing in the CONV HSCT
recipients. By 1 year posttransplantation, the incidence of
ADV in the stool was similar among the recipients of TCD,
unmodiﬁed, and cord blood allografts. In earlier work, we
reported a 9% incidence of ADV enteritis in TCD HCST recipi-
ents, suggesting a stable incidence rate of ADV enteritis at our
institution over the last decade [2]. In contrast, the incidence
of ADV viremia was signiﬁcantly higher in TCD HSCT recipi-
ents compared with CONV HSCT recipients (4% versus 7.9%).roup 2 (n ¼ 15) Group 3 (n ¼ 20)
.8  104 (1.1  104-1.4  105) 1.7  106 (2  105->1  1010)
8 (19-674) 91 (10-722)
9 (60) 8 (40)
9 (60) 16 (80)
4 (27) 7 (35)
3 (20) 11 (55)
9 (60) 17 (85)
9 (60) 4 (20)
7 (47) 9 (45)
emia 10,000 copies/mL; group 3: very-high-level ADV viremia (200,000
Figure 2. Comparison of ADV viral load (VL) in patients with ADV viremia
without disease (ADV viremia only) and those with ADV disease. First,
maximum, and last available ADV viral loads were compared in the 2 groups.
Patients with 3 or more positive ADV PCR reports were included. First VL
indicates ﬁrst positive ADV PCR; Mx VL, maximum ADV PCR; last VL, last
available ADV PCR. The y-axis shows ADV viral load log10 (copies/mL). In the
boxplots, the shaded areas represent the 5th to 95th percentile, whiskers
represent 95% CIs, circles represent outliers, and the horizontal line represents
the median. Signiﬁcant differences are marked. The maximum viral load was
higher in patients with ADV disease (P ¼ .014), as was the last available viral
load (P ¼ .031).
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was higher in pediatric patients compared with adults.
In agreement with previous studies [11,23,25], young age
andacuteGVHDwere identiﬁedas independent risk factors for
ADVviremia.ADVviremiawasaprognostic factor forworseOS.
Our approach of symptom-based testing likely skewed the
viremia population to a sicker group of patients with “signiﬁ-
cant” ADV viremia and profound immunosuppression.
A striking ﬁnding of our study is that although the inci-
dence of ADV viremia was only 2-fold higher in TCD HSCT
recipients compared with CONV HSCT recipients, the risk for
invasive ADV disease was roughly 10-fold higher in the TCD
cohort, suggesting the critical importance of donor T cells in
controlling viral replication. Immunity against viruses
depends largely on the recovery of T lymphocytes and
particularly of CD4þ T cells. After conventional grafts, such
recovery begins at approximately 2 to 4 months post-
transplantation [26]. The vast majority of ADV cases among
CONV HSCT recipients occurred up to 4 months post-
transplantation. Adult recipients of TCDallografts, particularly
those fromunrelated donors, exhibit prolonged states of Tcell
cytopenia and extreme CD4 lymphopenia. In contrast, recon-
stitution in pediatric recipients of TCD grafts resembles that
reported inchildrenafterautologousormatched siblingdonor
conventional transplantation. This suggests that differences in
the host environment, such as the lack of a thymus, might
underlie the limitations of immune recovery in adults [27]. In
fact, among TCD HSCT recipients, young age was not a risk
factor for ADV disease, in contrast to ADV viremia.
Performing ADV PCR based on clinical suspicion did not
lead to earlier diagnosis of ADV disease. The majority of
patients had established disease at the time of the ﬁrst
positive ADV PCR report. ADV disease was associated with an
all-cause mortality rate of 94% and was the primary cause of
death in approximately one-third of all cases. The highmortality rate of ADV disease further underscores the need
for safe and effective therapy for ADV.
The decision to start antiviral treatment for ADV viremia
was based on clinical presentation and the degree of
immunosuppression. We examined the outcomes of patients
with ADV viremia based on the magnitude of ADV viral load.
Eight patients (20%) had low-level ADV viremia (<10,000
copies/mL). Viremia was self-limited in all but 1 of these
patients, and there were no deaths associated with ADV.
Based on our ﬁndings, we suggest monitoring low-level
viremia by serial ADV PCR. In contrast, the majority of
patients with high-level ADV viremia failed to clear viremia
despite treatment with cidofovir. Interestingly, 3 patients
with ADV disease detected at autopsy died with a negative
ADV PCR report. In our cohort, one-third of the patients with
ADV viremia developed invasive disease. Among TCD HSCT
recipients, 58% of those with viremia developed ADV disease.
Ourdata indicate that preemptive therapy for ADVviremia
using a threshold of 10,000 copies/mL could be beneﬁcial,
especially in recipients of TCD allografts. Median viral load at
presentation was similar in patients who developed ADV
disease and those who did not, whereas the maximum and
last available viral loads were higher in patients with disease.
The decision to institute antiviral therapy was based on
individual patient risk for ADV disease. The last available viral
load varied widely in patients with ADV disease, reﬂecting
treatment effect or death with a high ADV viral load.
At present, there is no approved antiviral treatment for
ADV. Cidofovir has in vitro activity against ADV and has been
used for the treatment of invasive ADV disease, but its efﬁ-
cacy has not yet been evaluated in randomized clinical trials
[2,24,28-32]. Preemptive treatment for ADV viremia has not
been validated in clinical trials; thus, there is no established
ADV viral load threshold for the initiation of antiviral
therapy. Erard et al. [33] reported that sustained high-level
viremia was a sensitive indicator of disease, whereas Walls
et al. [11] reported that ADV viremia cleared spontaneously
in 7 of 11 children (3 TCD HSCT recipients and 4 CONV HSCT
recipients) monitored serially for ADV [11]. Cidofovir is not
an optimal candidate for preemptive therapy because of its
toxicity proﬁle, especially in the setting of compromised
renal function or concomitant use of nephrotoxic medica-
tion. The novel oral broad-spectrum antiviral agent CMX001
has activity against ADV and is currently in clinical trials for
preemptive treatment of ADV viremia in HSCT [34].
The transfer of ex vivo expanded T cells to restore
immunity to multiple viral pathogens could offer long-term
restoration of ADV-speciﬁc immunity in recipients of TCD
HSCT and cord blood HSCT [20,21,35-37]. Currently, logistical
constraints limit the broad applicability of this therapy.
Donor-derived antiviral cytotoxic T cells offer the potential to
effectively transfer antiviral immunity to viral pathogens
such as CMV and Epstein-Barr virus without the risk of
GVHD [38-40]. This approach is currently being developed
for ADV [35,41]. The presence of multiple ADV serotypes and
low numbers of circulating ADV-speciﬁc CTLs in healthy
donors are some of the challenges to adoptive immuno-
therapy for ADV.
Preemptive treatment prompted by a positive ADV PCR in
the absence of clinical symptoms could reducemorbidity and
potentially improve survival, if a safe and effective antiviral
agent were available. We did not examine the rates of
asymptomatic ADV viremia and thus cannot estimate the
number of patients needed to treat to prevent 1 case of ADV
disease.
Y.J. Lee et al. / Biol Blood Marrow Transplant 19 (2013) 387e392392The identiﬁcation of only a single case of ADV disease
among the 223 CONV HSCT recipients (including 92 cord
blood graft recipients) attests to the rarity of this complica-
tion in both adults and children receiving T cellereplete
grafts. High-risk groups, such as recipients of TCD allo-
grafts, could be a good target population for preemptive
therapy. Randomized clinical trials are needed to optimize
the management of ADV viremia, especially in recipients of
TCD HSCT and patients with GVHD.
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